Immunotherapy Drug Shrinks Tumors in Half of Patients with Rare, Virus-Linked Skin Cancer
Johns Hopkins MedicineIn a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy.